I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Hydroxychloroquine Retinal Toxicity: Screening, Risk, and Protecting Your Vision
What Is Hydroxychloroquine Retinal Toxicity?
Hydroxychloroquine retinal toxicity is a form of drug-induced retinopathy, meaning retinal damage caused directly by a medication. Understanding how this condition develops can help patients take an active role in their eye care.
Hydroxychloroquine has been used in the United States since 1955 and remains a widely prescribed treatment for several autoimmune diseases. Over time, the drug can accumulate in the retina, the thin layer of tissue at the back of the eye that converts light into the visual signals the brain interprets as sight. When accumulation reaches harmful levels, it damages the cells responsible for central and color vision.
When detected early, the extent of damage may be limited. If toxicity is not identified in time, it can progress to a pattern called bull's-eye maculopathy. This describes a ring of damaged tissue surrounding the center of the macula, the part of the retina responsible for the sharp, detailed vision needed for reading, driving, and recognizing faces.
Hydroxychloroquine affects the retina through several related processes. The drug binds to melanin, a natural pigment found in the retinal pigment epithelium (RPE). The RPE is a supportive cell layer that lies beneath the photoreceptors, the specialized cells that detect light and make vision possible.
Research has shown that hydroxychloroquine disrupts RPE cell function by damaging lysosomes, which are structures inside cells that break down and remove waste. The drug also reduces the ability of RPE cells to clear shed material from photoreceptor outer segments. When this debris accumulates, it leads to gradual RPE degeneration and loss of photoreceptors. Current evidence suggests that photoreceptors are likely affected first, with RPE damage developing afterward.
One of the most concerning aspects of hydroxychloroquine toxicity is that retinal damage can continue to worsen even after the medication has been stopped. Because the drug binds tightly to melanin in the RPE, it can remain stored in retinal tissue for a prolonged period. In some patients, measurable worsening has been documented in the year following the last dose. In more advanced cases, this ongoing progression can lead to significant or permanent central vision loss.
Risk Factors for Hydroxychloroquine Retinal Toxicity
Several factors influence a patient's likelihood of developing retinal toxicity. Understanding these factors helps determine how closely and how frequently monitoring needs to be scheduled.
The single most important risk factor is how long a patient takes the medication. According to the American Academy of Ophthalmology (AAO), the risk of developing retinal toxicity at recommended doses remains below 1% during the first five years of use and stays below 2% through 10 years. However, risk increases sharply with longer-term treatment. Research has measured an overall retinopathy rate of approximately 4.3% among long-term users, rising to around 11.5% between 16 and 20 years of continuous use. Some studies report prevalence reaching 20% to 50% after 20 years of exposure.
Taking more than the recommended daily dose meaningfully raises the risk of retinal damage. Current AAO guidelines recommend keeping the daily dose below 5.0 milligrams per kilogram of actual body weight. When dosing stays within this limit, the likelihood of toxicity within the first five years remains low. Patients who regularly exceed this threshold face a significantly higher risk of developing toxicity over time.
The kidneys are responsible for clearing hydroxychloroquine from the body. Patients with stage 3 kidney disease or worse, defined by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2, face a notably elevated risk. Research has found that reduced kidney function is associated with more than twice the odds of developing toxic retinopathy. When the kidneys cannot clear the drug efficiently, it accumulates to higher levels in retinal tissue over time.
Tamoxifen is a medication commonly used in the management of breast cancer. When taken alongside hydroxychloroquine, it has been associated with up to a five-fold increase in the risk of retinal toxicity, according to AAO research. Patients taking both medications should discuss this combined risk with their prescribing physician and schedule closer retinal monitoring from the start of treatment.
Several additional factors may further raise a patient's chance of developing retinal toxicity. These include:
- Pre-existing macular disease, which may make the retina more vulnerable to drug-related damage
- Higher cumulative lifetime dose of hydroxychloroquine
- Genetic factors that may influence how an individual's retina responds to the drug
Patients with any of these factors may benefit from closer monitoring beginning earlier in the course of treatment.
Signs and Symptoms of Hydroxychloroquine Toxicity
Hydroxychloroquine retinal toxicity is often completely silent in its earliest stages. Understanding what symptoms may eventually appear, and why measurable retinal damage so often precedes noticeable vision changes, is central to catching this condition in time.
In the early stages of hydroxychloroquine retinal toxicity, most patients do not notice any change in their vision. The retina can sustain measurable damage on imaging and specialized testing well before any symptoms arise. This is one of the primary reasons why structured, regular screening is so important for anyone taking hydroxychloroquine long-term.
In some early-stage cases, a patient may notice a paracentral scotoma, a small blind spot located just off the center of the visual field. This can cause subtle difficulty with reading. Some patients also report early, mild changes in color perception.
As the condition progresses, symptoms become more noticeable and disruptive. These may include:
- Reduced central vision or blurry vision
- Paracentral scotomas, meaning blind spots near the center of the visual field
- Photopsia, which refers to perceived flashes of light
- Increased sensitivity to glare
- Difficulty reading or recognizing faces
In later stages, hydroxychloroquine toxicity can lead to reduced visual sharpness, loss of peripheral vision, and difficulty seeing in low-light settings. By the time patients notice significant symptoms, substantial and often irreversible retinal damage has already occurred.
The most recognizable sign of advanced hydroxychloroquine toxicity is bull's-eye maculopathy. This describes a ring of damaged RPE and photoreceptor cells surrounding a relatively preserved central area of the macula, a pattern clearly visible on retinal imaging and examination. When this pattern is present, significant retinal damage has already taken place. The entire purpose of routine screening is to detect toxicity well before this stage develops.
Screening and Diagnosis
Detecting hydroxychloroquine retinal toxicity early requires a structured program that uses multiple imaging and functional tests. Our retina specialists work in close coordination with rheumatologists and other prescribing physicians to make sure patients are monitored at the right intervals with the right tools.
The AAO recommends that all patients starting hydroxychloroquine receive a baseline eye examination within the first year of treatment. This exam establishes a detailed picture of retinal health before any toxicity can develop, providing a reference point for all future screenings. A complete baseline evaluation includes measurement of best corrected visual acuity, automated threshold visual field testing of the central 10 degrees of vision, and spectral domain optical coherence tomography (SD-OCT). SD-OCT is a non-invasive imaging test that captures detailed cross-sectional images of the retinal layers, making it possible to detect subtle structural changes over time.
For patients without significant risk factors, the AAO recommends beginning annual retinal examinations after five years of hydroxychloroquine use. For those with one or more risk factors, including a daily dose above 5.0 mg/kg of actual body weight, reduced kidney function, concurrent tamoxifen use, or pre-existing macular disease, annual screening is recommended from the very beginning of treatment. Consistently following this schedule is the most reliable way to detect early toxicity before vision is affected.
Several specialized tests are used together to identify early signs of retinal toxicity. These include:
- Spectral domain optical coherence tomography (SD-OCT), which can reveal thinning or structural disruption of the outer retinal layers before any symptoms are present
- Automated visual field testing of the central 10 degrees, which can identify paracentral scotomas a patient may not yet be aware of
- Multifocal electroretinography (mfERG), which measures the electrical response of the retina across specific regions to detect functional changes
- Fundus autofluorescence (FAF) imaging, which highlights abnormal patterns in the retinal pigment epithelium
Using multiple tests together provides the most complete picture of retinal health and improves the ability to detect subtle early changes before they progress.
Research has shown that patients of Asian descent are more likely to develop retinal toxicity in a pattern that extends beyond the central macula into more peripheral areas of the retina. Standard central 10-degree visual field testing alone may not detect damage in these areas. Wider visual field testing is often recommended for these patients to ensure full retinal coverage. A retina specialist familiar with these patterns can tailor the screening approach to the individual's needs.
Treatment and Management After Toxicity Is Detected
When retinal toxicity is found, there are important steps a patient and their care team can take together. While no treatment can undo damage that has already occurred, preventing further injury is a meaningful and achievable goal.
There is currently no medication, laser procedure, or surgical intervention that can repair or restore retinal cells damaged by hydroxychloroquine. Photoreceptors and RPE cells that have been lost cannot be recovered with any currently available therapy. This makes early detection through consistent screening the most powerful tool available. Preventing additional damage is far more achievable than trying to repair what has already been lost.
When a retina specialist identifies signs of toxicity, the primary recommendation is to discontinue hydroxychloroquine. This decision should be made in close coordination with the rheumatologist or other prescribing physician managing the underlying autoimmune condition. Stopping the medication removes the ongoing source of retinal damage. However, because the drug can remain bound to retinal tissue for an extended period after the last dose, discontinuation does not guarantee that damage will halt immediately.
Patients who must stop hydroxychloroquine due to retinal toxicity will need to work with their prescribing physician to find a suitable alternative. Several immunomodulatory and immunosuppressive medications are available for conditions such as lupus and rheumatoid arthritis. The best choice depends on the specific autoimmune condition being managed and the patient's overall health profile. This transition should be handled carefully to keep the underlying disease under effective control.
Outlook and Long-Term Monitoring
The prognosis after hydroxychloroquine retinal toxicity is detected depends significantly on how early the damage was identified. Long-term follow-up with a retina specialist remains important regardless of the stage at which toxicity was found.
When toxicity is identified at a very early stage, before significant photoreceptor loss has occurred, the outlook is generally more favorable. Mild damage may stabilize, and some patients experience modest improvement after the medication is stopped. Even so, the retina has a limited capacity to repair itself. Some degree of damage may remain even after hydroxychloroquine is discontinued, and continued monitoring is needed to track any ongoing changes over time.
When toxicity is identified at an advanced stage, or when bull's-eye maculopathy has already developed, the prognosis is more serious. Vision loss at this stage is typically permanent. Damage may continue to progress for a year or more after the last dose, as the drug remains bound to retinal tissue. Patients may experience worsening central vision, expanding blind spots, or further difficulty seeing in low-light conditions. Close monitoring after stopping the medication helps track these changes and guide any supportive care decisions.
After hydroxychloroquine is discontinued due to confirmed toxicity, ongoing monitoring by a retina specialist remains essential. Follow-up appointments allow our team to assess whether damage has stabilized or continues to evolve. OCT imaging and visual field testing are typically repeated at regular intervals to document any changes and to inform decisions about supportive care or vision rehabilitation referrals.
Living Well With Hydroxychloroquine Retinal Toxicity
Patients who have experienced retinal damage from hydroxychloroquine can take meaningful steps to protect their remaining vision and maintain quality of life. Effective management of this condition extends well beyond the clinic.
Wearing UV-protective sunglasses when outdoors helps reduce additional light-related stress on the retina. Keeping up with routine comprehensive eye exams is also important, since other conditions such as cataracts or glaucoma can compound existing vision challenges. Every eye care provider a patient sees should be informed of the history of hydroxychloroquine use and any confirmed diagnosis of retinal toxicity.
For patients who have experienced significant vision loss, low vision rehabilitation can help maximize the use of remaining sight. Low vision specialists evaluate functional vision and recommend practical solutions tailored to the individual. These may include magnifying devices, specialized lighting, large-print materials, and assistive technologies such as screen readers. With the right tools and support, many patients can continue to read, work, and maintain independence even when central vision has been reduced.
Managing hydroxychloroquine retinal toxicity well requires ongoing communication between the patient, the retina specialist, and the physician overseeing the autoimmune condition. Patients should promptly report any new or worsening visual symptoms to their retina specialist, even between scheduled appointments. Keeping all members of the care team informed about medication changes and visual symptoms helps ensure that both the autoimmune disease and the retinal condition are managed as effectively as possible.
When to See a Retina Specialist
Knowing when to make an appointment, and when to seek care without delay, is an important part of protecting your vision while taking hydroxychloroquine.
Any patient about to begin hydroxychloroquine therapy should schedule a baseline retinal examination with a retina specialist before or shortly after starting treatment. This exam establishes a detailed record of retinal health, making it much easier to identify subtle changes during future screenings. The AAO recommends this baseline evaluation be completed within the first year of starting the medication.
Patients taking hydroxychloroquine should follow the screening schedule recommended by the AAO. Those without additional risk factors should begin annual retinal examinations after five years of use. Those with risk factors such as higher dosage, reduced kidney function, tamoxifen use, or existing macular disease should be seen annually from the beginning of treatment. Consistent adherence to this schedule provides the most reliable protection available.
Any patient taking hydroxychloroquine who notices new or changing visual symptoms should contact a retina specialist promptly, without waiting for the next scheduled appointment. Symptoms such as new blind spots, difficulty reading, changes in color vision, or increased sensitivity to glare may indicate developing toxicity and should never be attributed to normal aging without a thorough examination. Acting early gives the best opportunity to limit further damage.
Frequently Asked Questions
Here are answers to some of the questions patients most often ask about hydroxychloroquine retinal toxicity, including what to expect and how to navigate care decisions.
If your retina specialist finds no signs of toxicity during your screening exams, you can generally continue taking hydroxychloroquine as prescribed by your rheumatologist or other physician. Screening exists precisely to catch early changes before they become significant, giving your care team the ability to act while options are still available. As long as exams remain normal and your daily dose stays at or below 5.0 mg/kg of actual body weight, the benefits of hydroxychloroquine for your autoimmune condition generally outweigh the current risk of retinal damage for most patients. Your retina specialist and prescribing physician can help weigh those considerations with you directly.
Retinal toxicity is uncommon in the first several years of hydroxychloroquine use. According to AAO data, the risk remains below 1% during the first five years and below 2% through 10 years. After 10 to 15 years of continuous use, risk increases more substantially. The exact timeline varies based on dosage, kidney function, genetics, and other individual factors. This variability is why both baseline and follow-up exams remain important even for patients who feel no symptoms and have been on the medication for only a few years.
The outcome depends heavily on how early the toxicity was detected. When damage is caught at a very early stage, some stabilization or modest improvement is possible after stopping the medication. In many cases, however, retinal damage from hydroxychloroquine is irreversible, and some patients experience continued worsening for up to a year or more after the last dose because the drug remains bound to retinal tissue. There is no guarantee of vision recovery, which is exactly why early detection through regular screening is so important. Stopping the medication removes the ongoing source of damage, even when full vision restoration is not possible.
No supplements, vitamins, or eye drops have been proven to protect the retina from hydroxychloroquine toxicity. The most effective strategies remain keeping the daily dose within the AAO-recommended limit, following a regular screening schedule, and stopping the medication promptly if early signs of toxicity are found. Over-the-counter products should never be used as a substitute for proper retinal monitoring. If you have questions about specific supplements and your eye health, bring them up at your next retina appointment so your specialist can provide guidance tailored to your situation.
Short-term use carries a very low risk of retinal toxicity. When the medication is prescribed for a limited course, such as during a short-term inflammatory flare, the cumulative dose is typically far too small to cause meaningful retinal damage in the vast majority of patients. The risk of toxicity is primarily associated with continuous, long-term use over many years. If you have a pre-existing retinal condition, other risk factors, or any uncertainty about your situation, a retina specialist can review your case and provide guidance specific to your health history.
Schedule a Retinal Screening Consultation
If you are taking hydroxychloroquine or are about to begin treatment, our team at New England Retina Associates is here to provide expert, attentive retinal care at our offices throughout Connecticut. We offer the full range of specialized testing needed to monitor for early toxicity and work closely with your prescribing physicians so your entire care team stays informed. We encourage you to schedule a baseline exam or annual screening appointment and take an active, confident role in protecting your vision.
30 Years of Care & Commitment
